Nabriva Therapeutics AG (NASDAQ:NBRV) has earned an average recommendation of “Buy” from the seven analysts that are covering the firm. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $15.89.
A number of research analysts recently commented on the company. Zacks Investment Research cut Nabriva Therapeutics AG from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Nabriva Therapeutics AG in a research report on Tuesday, August 9th. Finally, HC Wainwright initiated coverage on shares of Nabriva Therapeutics AG in a research report on Thursday, September 8th. They set a “buy” rating and a $16.00 price target for the company.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded up 0.14% during mid-day trading on Wednesday, reaching $7.16. The company had a trading volume of 53,409 shares. The company’s market capitalization is $152.20 million. The firm has a 50-day moving average of $7.52 and a 200-day moving average of $7.94. Nabriva Therapeutics AG has a 12-month low of $6.61 and a 12-month high of $10.69.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Tuesday, August 9th. The company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($6.25) by $5.75. On average, equities analysts anticipate that Nabriva Therapeutics AG will post ($1.93) earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of NBRV. Vivo Capital LLC purchased a new stake in Nabriva Therapeutics AG during the first quarter worth $28,239,000. Opaleye Management Inc. raised its stake in Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Jackson Park Capital LLC purchased a new stake in Nabriva Therapeutics AG during the second quarter worth $195,000. Institutional investors own 63.05% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.